Optimizing end points and outcomes in cancer-associated wasting

J Clin Oncol. 2005 Apr 20;23(12):2871-2; author reply 2872-3. doi: 10.1200/JCO.2005.05.269.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Appetite / drug effects
  • Appetite Stimulants / administration & dosage
  • Appetite Stimulants / adverse effects
  • Appetite Stimulants / therapeutic use
  • Eicosapentaenoic Acid / administration & dosage
  • Eicosapentaenoic Acid / adverse effects
  • Eicosapentaenoic Acid / therapeutic use
  • Endpoint Determination*
  • Humans
  • Megestrol Acetate / administration & dosage
  • Megestrol Acetate / adverse effects
  • Megestrol Acetate / therapeutic use
  • Neoplasms / complications*
  • Reproducibility of Results
  • Wasting Syndrome / drug therapy*
  • Wasting Syndrome / etiology*
  • Weight Gain

Substances

  • Appetite Stimulants
  • Eicosapentaenoic Acid
  • Megestrol Acetate